Teva says it now has approval for all dosages, and will launch the new forms immediately. US brand sales of the capsule form of the drug totaled $2.1 billion in 2001.
Israeli drug manufacturer Teva (Nasdaq: TEVA) announced yesterday that the US FDA had granted it final approval for various dosages of Fluoxetine, the generic version of the Eli Lilly’s antidepressant Prozac. Teva received approval for three dosages in capsule form and for one dosage in tablet form. US brand sales of the capsule form of the drug totaled $2.1 billion in 2001.
Teva says it now has approval for all Fluoxetine dosages, and will launch the new forms immediately. The approval comes after a six-month period of exclusivity for certain drug manufacturers to produce versions of Prozac ended on Tuesday. Eli Lilly’s patent protection for Prozac ended last August.
Teva shares were up 1% at NIS 286 in early trade on the Tel Aviv Stock Exchange on Wednesday.
Published by Israel's Business Arena on 30 January, 2002